Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Risk Factors for Severe COVID-19 and Hospital Admission in Patients With Inborn Errors of Immunity - Results From a Multicenter Nationwide Study

T. Milota, M. Sobotkova, J. Smetanova, M. Bloomfield, J. Vydlakova, Z. Chovancova, J. Litzman, R. Hakl, J. Novak, I. Malkusova, J. Hanzlikova, D. Jilek, B. Hutyrova, V. Novak, I. Krcmova, A. Sediva, P. Kralickova

. 2022 ; 13 (-) : 835770. [pub] 20220228

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22010931

Despite the progress in the understanding how COVID-19 infection may impact immunocompromised patients, the data on inborn errors of immunity (IEI) remain limited and ambiguous. Therefore, we examined the risk of severe infection course and hospital admission in a large cohort of patients with IEI. In this multicenter nationwide retrospective survey-based trial, the demographic, clinical, and laboratory data were collected by investigating physicians from 8 national referral centers for the diagnosis and treatment of IEI using a COVID-19-IEI clinical questionnaire. In total, 81 patients with IEI (including 16 with hereditary angioedema, HAE) and confirmed SARS-CoV-2 infection were enrolled, and were found to have a 2.3-times increased (95%CI: 1.44-3.53) risk ratio for hospital admission and a higher mortality ratio (2.4% vs. 1.7% in the general population). COVID-19 severity was associated with the presence of clinically relevant comorbidities, lymphopenia, and hypogammaglobulinemia, but not with age or BMI. No individuals with HAE developed severe disease, despite a hypothesized increased risk due to perturbed bradykinin metabolism. We also demonstrated a high seroconversion rate in antibody-deficient patients and the safety of anti-spike SARS CoV-2 monoclonal antibodies and convalescent plasma. Thus, IEI except for HAE, represent significant risk factors for a severe COVID-19. Therefore, apart from general risk factors, immune system dysregulation may also be involved in the poor outcomes of COVID-19. Despite the study limitations, our results support the findings from previously published trials.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22010931
003      
CZ-PrNML
005      
20220506131115.0
007      
ta
008      
220425s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fimmu.2022.835770 $2 doi
035    __
$a (PubMed)35296097
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Milota, Tomas $u Department of Immunology, Second Faculty of Medicine Charles University and Motol University Hospital, Prague, Czechia
245    10
$a Risk Factors for Severe COVID-19 and Hospital Admission in Patients With Inborn Errors of Immunity - Results From a Multicenter Nationwide Study / $c T. Milota, M. Sobotkova, J. Smetanova, M. Bloomfield, J. Vydlakova, Z. Chovancova, J. Litzman, R. Hakl, J. Novak, I. Malkusova, J. Hanzlikova, D. Jilek, B. Hutyrova, V. Novak, I. Krcmova, A. Sediva, P. Kralickova
520    9_
$a Despite the progress in the understanding how COVID-19 infection may impact immunocompromised patients, the data on inborn errors of immunity (IEI) remain limited and ambiguous. Therefore, we examined the risk of severe infection course and hospital admission in a large cohort of patients with IEI. In this multicenter nationwide retrospective survey-based trial, the demographic, clinical, and laboratory data were collected by investigating physicians from 8 national referral centers for the diagnosis and treatment of IEI using a COVID-19-IEI clinical questionnaire. In total, 81 patients with IEI (including 16 with hereditary angioedema, HAE) and confirmed SARS-CoV-2 infection were enrolled, and were found to have a 2.3-times increased (95%CI: 1.44-3.53) risk ratio for hospital admission and a higher mortality ratio (2.4% vs. 1.7% in the general population). COVID-19 severity was associated with the presence of clinically relevant comorbidities, lymphopenia, and hypogammaglobulinemia, but not with age or BMI. No individuals with HAE developed severe disease, despite a hypothesized increased risk due to perturbed bradykinin metabolism. We also demonstrated a high seroconversion rate in antibody-deficient patients and the safety of anti-spike SARS CoV-2 monoclonal antibodies and convalescent plasma. Thus, IEI except for HAE, represent significant risk factors for a severe COVID-19. Therefore, apart from general risk factors, immune system dysregulation may also be involved in the poor outcomes of COVID-19. Despite the study limitations, our results support the findings from previously published trials.
650    _2
$a dospělí $7 D000328
650    _2
$a COVID-19 $x epidemiologie $7 D000086382
650    _2
$a komorbidita $7 D015897
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a hospitalizace $x statistika a číselné údaje $7 D006760
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a primární imunodeficience $x epidemiologie $7 D000081207
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a rizikové faktory $7 D012307
650    _2
$a SARS-CoV-2 $x fyziologie $7 D000086402
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a průzkumy a dotazníky $7 D011795
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sobotkova, Marta $u Department of Immunology, Second Faculty of Medicine Charles University and Motol University Hospital, Prague, Czechia
700    1_
$a Smetanova, Jitka $u Department of Immunology, Second Faculty of Medicine Charles University and Motol University Hospital, Prague, Czechia
700    1_
$a Bloomfield, Marketa $u Department of Immunology, Second Faculty of Medicine Charles University and Motol University Hospital, Prague, Czechia $u Department of Paediatrics, First Faculty of Medicine, Charles University in Prague, Prague, Czechia
700    1_
$a Vydlakova, Jana $u Department of Clinical and Transplant Immunology, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Chovancova, Zita $u Department of Allergology and Clinical Immunology, Faculty of Medicine, Masaryk University and St Anne's University Hospital in Brno, Brno, Czechia
700    1_
$a Litzman, Jiri $u Department of Allergology and Clinical Immunology, Faculty of Medicine, Masaryk University and St Anne's University Hospital in Brno, Brno, Czechia
700    1_
$a Hakl, Roman $u Department of Allergology and Clinical Immunology, Faculty of Medicine, Masaryk University and St Anne's University Hospital in Brno, Brno, Czechia
700    1_
$a Novak, Jiri $u Center for Clinical Immunology, Hospital Ceske Budejovice, Ceske Budejovice, Czechia
700    1_
$a Malkusova, Ivana $u Department of Immunology and Allergology, Faculty of Medicine and Faculty Hospital in Pilsen, Charles University in Prague, Pilsen, Czechia
700    1_
$a Hanzlikova, Jana $u Department of Immunology and Allergology, Faculty of Medicine and Faculty Hospital in Pilsen, Charles University in Prague, Pilsen, Czechia
700    1_
$a Jilek, Dalibor $u Department of Allergology and Clinical Immunology, Institute of Health in Usti nad Labem, Usti nad Labem, Czechia
700    1_
$a Hutyrova, Beata $u Department of Allergology and Clinical Immunology, University Hospital in Olomouc, Olomouc, Czechia
700    1_
$a Novak, Vitezslav $u Department of Immunology and Allergy, Institute of Health in Ostrava, Ostrava, Czechia
700    1_
$a Krcmova, Irena $u Institute of Clinical Immunology and Allergy, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove, Charles University, Hradec Kralove, Czechia
700    1_
$a Sediva, Anna $u Department of Immunology, Second Faculty of Medicine Charles University and Motol University Hospital, Prague, Czechia
700    1_
$a Kralickova, Pavlina $u Institute of Clinical Immunology and Allergy, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove, Charles University, Hradec Kralove, Czechia
773    0_
$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 13, č. - (2022), s. 835770
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35296097 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506131107 $b ABA008
999    __
$a ok $b bmc $g 1788853 $s 1162129
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 13 $c - $d 835770 $e 20220228 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace